A company born out of UWA research and seeking to provide a circuit breaker to antimicrobial resistance will look to raise $28 million as it nears a crucial juncture of the preclinical stage.
A Perth-founded company developing a drug to combat antimicrobial resistance has added several high-profile names to its ranks, including philanthropist John Poynton.
A promising new drug invented at UWA is set to begin clinical trials, which will observe whether, when paired with antibiotics, it can help treat chronic bacterial lung infections.
Perth startup Lixa is on the path to commercialising medical research from the University of Western Australia after gaining backing from tech hub CERI and raising $2.2 million.
